Abstract 5196: Novel humanized CD36 mouse model for therapeutic studies

Abstract Activation of oncogenic signaling pathways can be mediated by various transporters on tumor cells that facilitate trafficking of lipids. CD36 has been identified as a fatty acid transporter and participates in tumor growth and drug resistance. To explore potential therapeutic strategies targeting CD36, we generated a human CD36 knockout/knock-in in situ (B-hCD36) mouse model to evaluate the efficacy of anti-human CD36 antibodies. We first confirmed human CD36 gene and protein expression in B-hCD36 mice by RT-PCR and flow cytometry, respectively. We next observed that the overall development, differentiation, and distribution of splenic, blood and lymph node immune cells were similar between wild-type C57BL/6 and B-hCD36 mice. Lastly, in vivo efficacy studies using anti-human CD36 antibodies alone or in combination with anti-mouse PD-1 antibodies, were effective in controlling MC38 tumor growth in B-hCD36 mice. Our data demonstrates that B-hCD36 mice are a powerful preclinical model for in vivo efficacy evaluation of anti-human CD36 antibodies. Citation Format: Linlin Wang, Chang Liu, Rebecca Soto, Chengzhang Shang, Qingcong Lin. Novel humanized CD36 mouse model for therapeutic studies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5196.